Infection by many Category A, B, and C Priority Pathogens activates the innate immune system triggering an exuberant release of cytokines and other permeability factors that destabilize the endothelial barrier. The loss of vascular integrity results in non-cardiogenic edema, shock, multi-organ failure and death. We propose a new and broad therapeutic platform for reducing morbidity and mortality based on our identification of an endothelial receptor, Robo4. Activation of the Robo4 receptor by its ligand , Slit proteins, preserves the integrity of the endothelial barrier and interferes with the downstream signaling cascades from multiple permeability factors including TNF-alpha, interleukins, and thrombin in the endothelium. In animal models, Robo4 stabilizes the endothelium following diverse insults including mechanical injury, ischemia, and cytokine storm. We have recently demonstrated that in two rodent models of pathogen induced acute lung injury, this approach reduced edema, shock and death. Ultimately, our goal is to create a single platform for treating infections from a variety of Category A, B and C priority pathogens.
AIM 1 : Determine efficacy of Robo4 peptide agonist in rodent models of viral hemorrhagic fevers. We will use viral hemorrhagic fever models to examine whether activating Robo4 in these non-influenza viral pathogens (arenavirus hemorrhagic fever virus) reduces mortality.
This Aim i s facilitated by an active collaborative effort that has already established efficacy in bacterial endotoxin and H5N1 animal models.
AIM 2 : Optimize a Robo4 peptide agonist. We will optimize recombinant Slit-like peptide capable of activating the Robo4 signaling pathway by serial mutagenesis. Studies will focus on delivery, stability, and production requirements needed to prepare for future GMP/GLP studies.
AIM 3 : Robo signaling in endothelial and epithelial integrity. We will determine whether Slit-Robo4 enhances endothelial cell-cell interactions, and seek to understand the molecular mechanism. We will use this as a model to investigate whether Slit-Robo1 signaling plays a similar role in epithelial-cell-cell contacts. This project fits within the RMRCE Integrated Research Focus on Viral Therapeutics and over the course of the five year period will interact directly with RP3.1, 3.2, 2.3 and cores C, D, and F.

Public Health Relevance

At present, there is an emphasis on developing different drugs for different pathogens. We will explore a strategy based on blunting the vascular response to cytokines that may provide a common platform for treating multiple pathogens.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54AI065357-08
Application #
8375717
Study Section
Special Emphasis Panel (ZAI1-DDS-M)
Project Start
Project End
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
8
Fiscal Year
2012
Total Cost
$355,416
Indirect Cost
$74,783
Name
Colorado State University-Fort Collins
Department
Type
DUNS #
785979618
City
Fort Collins
State
CO
Country
United States
Zip Code
80523
Lehman, Stephanie S; Mladinich, Katherine M; Boonyakanog, Angkana et al. (2016) Versatile nourseothricin and streptomycin/spectinomycin resistance gene cassettes and their use in chromosome integration vectors. J Microbiol Methods 129:8-13
Knudson, Susan E; Cummings, Jason E; Bommineni, Gopal R et al. (2016) Formulation studies of InhA inhibitors and combination therapy to improve efficacy against Mycobacterium tuberculosis. Tuberculosis (Edinb) 101:8-14
Charley, Phillida A; Wilusz, Jeffrey (2016) Standing your ground to exoribonucleases: Function of Flavivirus long non-coding RNAs. Virus Res 212:70-7
Phillips, Aaron T; Rico, Amber B; Stauft, Charles B et al. (2016) Entry Sites of Venezuelan and Western Equine Encephalitis Viruses in the Mouse Central Nervous System following Peripheral Infection. J Virol 90:5785-96
Westover, Jonna B; Sefing, Eric J; Bailey, Kevin W et al. (2016) Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses. Antiviral Res 126:62-8
Shankar, Sundaresh; Whitby, Landon R; Casquilho-Gray, Hedi E et al. (2016) Small-Molecule Fusion Inhibitors Bind the pH-Sensing Stable Signal Peptide-GP2 Subunit Interface of the Lassa Virus Envelope Glycoprotein. J Virol 90:6799-807
York, Joanne; Nunberg, Jack H (2016) Myristoylation of the Arenavirus Envelope Glycoprotein Stable Signal Peptide Is Critical for Membrane Fusion but Dispensable for Virion Morphogenesis. J Virol 90:8341-50
Rhodes, Katherine A; Schweizer, Herbert P (2016) Antibiotic resistance in Burkholderia species. Drug Resist Updat 28:82-90
Voge, Natalia V; Perera, Rushika; Mahapatra, Sebabrata et al. (2016) Metabolomics-Based Discovery of Small Molecule Biomarkers in Serum Associated with Dengue Virus Infections and Disease Outcomes. PLoS Negl Trop Dis 10:e0004449
Rico, Amber B; Phillips, Aaron T; Schountz, Tony et al. (2016) Venezuelan and western equine encephalitis virus E1 liposome antigen nucleic acid complexes protect mice from lethal challenge with multiple alphaviruses. Virology 499:30-39

Showing the most recent 10 out of 244 publications